A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy

Trial Profile

A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Febrile neutropenia
  • Focus Therapeutic Use
  • Acronyms PROTECT-1
  • Sponsors Sandoz
  • Most Recent Events

    • 07 Jun 2016 Results of a pooled analysis from PROTECT1 and PROTECT2 trials (n=624) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2015 Primary endpoint has been met. (Duration of symptoms), as per an abstract presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top